BOCH
MPLT

Blue Owl Capital Holdings’s MapLight Therapeutics MPLT Stock Holding History

Blue Owl Capital Holdings’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.2M Sell
729,929
-276,000
-27% -$7.94M 3.94% 6
2026
Q1 		$20.5M Buy
1,005,929
+678,871
+208% +$12.1M 5.49% 7
2025
Q4 		$5.74M Buy
+327,058
New +$5.48M 1.77% 17

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Blue Owl Capital Holdings's MPLT Position: Q2 2026 in Review

Blue Owl Capital Holdings reduced its MapLight Therapeutics (MPLT) stake by 27% in Q2 2026, selling an estimated $7.94M and leaving 729,929 shares worth $26.2M. The position accounts for 3.94% of the portfolio, ranked #6.

Blue Owl Capital Holdings first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Blue Owl Capital Holdings held 729,929 shares of MapLight Therapeutics worth $26.2M as of Q2 2026.
  • Blue Owl Capital Holdings sold 276,000 MapLight Therapeutics shares in Q2 2026, an estimated $7.94M.
  • MapLight Therapeutics made up 3.94% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #6 holding.
  • Blue Owl Capital Holdings first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 105 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.